You are here
Assembly Biosciences to Present at Upcoming Investor Conferences
SAN FRANCISCO, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), today announced that the company will be participating in the following upcoming investor conferences in September:
- Baird Global Healthcare Conference: Uri Lopatin, MD, Chief Medical Officer, will participate in a fireside chat on September 5, 2018, at 8:30 a.m. E.T. in New York.
- Morgan Stanley Global Healthcare Conference: Richard Colonno, PhD, Executive Vice President and Chief Scientific Officer Virology Operations, will participate in a fireside chat on September 12, 2018, at 10:30 a.m. E.T. in New York.
A live audio webcast of the fireside chat at the Morgan Stanley conference will be available at investor.assemblybio.com, and a replay will be available for approximately 30 days.
About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live synthetic biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.
Assembly Biosciences, Inc.